Revvity stock trades below recent high as revenue grows and margins expand

Revvity stock mirrors a company in transition that is still delivering growth, with Revvity Inc. (US76155R1086) reporting full-year 2023 revenue of about $2.98 billion and improved profitability while the shares remain below their recent 52-week high as of 22 July 2026, according to data from major market portals.

Revenue near $3 billion in 2023

Revvity Inc., the rebranded life-science tools and diagnostics business formerly part of PerkinElmer, generated approximately $2.98 billion in total revenue in fiscal 2023, according to the companys published annual figures and widely cited financial-statements summaries for that year. That compared with roughly $3.30 billion in the prior-year period, reflecting the expected normalization after the pandemic-related testing peak but leaving the company with a substantially larger revenue base than before the Covid-19 period.

Within this 2023 performance, recurring revenue from reagents, services, and informatics continued to form a significant portion of the business mix, supporting more stable cash flows even as Covid-19 testing revenue declined year on year. Market commentators who track Revvitys filings note that the 2023 revenue figure implies only a mid-single-digit percentage decrease versus 2022 when excluding Covid-related sales, underlining the resilience of its core life-science and diagnostics franchises.

Adjusted earnings and margin improvement

Profitability metrics for 2023 showed that Revvity was able to protect and even expand margins despite the top-line comparison headwind. On an adjusted basis, the company reported earnings per share for 2023 that were modestly higher than the prior year when normalized for the deconsolidation of divested businesses, according to consensus-style compilations of its annual report and associated management commentary. This improvement was driven by cost discipline, portfolio focus on higher-value segments, and ongoing integration of acquired technologies.

At the operating level, adjusted EBITDA in 2023 increased versus 2022 on a continuing-operations basis, with margin expansion visible in high-teens to low-twenties percentages, as summarized by financial-data services that follow Revvitys filings. The combination of a nearly $3 billion revenue base and expanding EBITDA margin has positioned the company to generate solid free cash flow that can be reinvested in research and development, bolt-on acquisitions, and debt reduction.

Quantified comparison versus prior year

The contrast between 2022 and 2023 illustrates how Revvity is navigating post-pandemic normalization. Market data derived from Revvitys reported results indicate that total revenue declined from roughly $3.30 billion in 2022 to about $2.98 billion in 2023, a decrease of a little less than 10%, driven primarily by lower Covid-19 testing revenue. When isolating non-Covid businesses, analysts note that underlying revenue grew on a mid-single-digit basis, highlighting that life-science and diagnostics demand remained positive on a like-for-like basis.

On the earnings side, the same data sets show that adjusted earnings per share for 2023 rose compared with 2022 after excluding divested units, demonstrating that margin improvements offset the revenue headwind. This quantified comparison underscores that Revvity has shifted from a pandemic-boosted revenue profile toward a more balanced model where margin management and recurring revenue play a greater role in value creation.

Market valuation and share-price context

From a market perspective, Revvity stock is listed in the United States and widely followed on major exchanges, with financial portals indicating that the company commanded a market capitalization around the mid-single-digit billions of dollars range as of 22 July 2026. At that point, the shares traded below their 52-week high, which is reported in the upper double-digit dollar area, while remaining above their 52-week low in the lower double-digit dollar band, according to composite quote summaries.

This positioning between the 52-week low and high suggests that investors have already repriced the stock from its peak optimism levels, yet still value the company for its durable life-science and diagnostics franchises. For investors, the relationship between the current share price, the roughly $2.98 billion 2023 revenue base, and the improving adjusted EBITDA margin is a key factor in assessing whether Revvity stock offers a compelling risk-reward profile at its present valuation.

Genomics, imaging, and diagnostics portfolio

Revvity has built a portfolio that spans genomics workflows, imaging systems, and clinical diagnostics solutions, giving the company exposure to diverse end markets such as pharmaceutical research, biotechnology, and hospital laboratories. These activities include instruments, reagents, and software that help customers perform high-throughput screening, molecular testing, and advanced imaging in areas like oncology, reproductive health, and infectious disease.

In recent years the company has expanded its capabilities through targeted acquisitions and internal research, aiming to increase the proportion of revenue coming from higher-growth and higher-margin areas such as next-generation sequencing workflows and informatics. Segment disclosures in recent filings show that life-sciences and diagnostics together contribute the vast majority of the approximately $2.98 billion revenue base, underlining the central role of these product lines in Revvitys long-term growth narrative.

Revvity stock and current trading level

As of 22 July 2026, widely used quote services show Revvity stock changing hands on its primary U.S. listing at a price in the mid-double-digit dollar range per share, with daily trading volume that fits its profile as a mid-cap life-science tools company. At this level, the shares are below their 52-week high but remain comfortably above the 52-week low, and the inferred market capitalization in the mid-single-digit billions of dollars reflects investors expectations for continued revenue growth from the roughly $2.98 billion 2023 base and further margin expansion over time.